In the autoimmune disease treatment drug ‘Humira’ market, biosimilar products are not showing remarkable activity in the early stages. Although it has been two years since domestic companies penetrated the market, the market share of ‘Humira’ biosimilar has passed two years, but the market share was only 12%. It is analyzed that the price of original drugs and biosimilars did not show an explosive rise because the insurance price was similar.

According to IQVIA, a pharmaceutical research institute on the 7th, the market for adalimumab ingredients in the first quarter was 24.5 billion won, up 9.8% from 22.3 billion won in the same period last year. Adalimumab is a TNF-alpha inhibitor that treats autoimm